Clinical Trial Update: Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing safety, tolerability, and pharmacokinetics of nintedanib in combination with pirfenidone in idiopathic pulmonary fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)
• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2018-02-13